产品封面图

FITC标记的血管内皮细胞生长因子受体3抗体

收藏
  • ¥2980
  • LMAI Bio
  • LM-2202R-FITC
  • 中国/美国/欧洲
  • 2025年07月12日
  • Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200
  • Human, Mouse, Rat,
  • Human, Mouse, Rat,
avatar
  • 企业认证

    点击 QQ 联系

    • 详细信息
    • 文献和实验
    • 技术资料
    • 供应商

      上海联迈生物工程有限公司

    • 库存

      大量

    • 靶点

      详见说明书

    • 级别

      1

    • 目录编号

      LM-2202R-FITC

    • 克隆性

      多克隆

    • 抗原来源

      Rabbit

    • 保质期

      1年

    • 抗体英文名

      Anti-VEGFR3/FITC

    • 抗体名

      Anti-VEGFR3/FITC

    • 标记物

      FITC标记

    • 宿主

      Human, Mouse, Rat,

    • 适应物种

      Human, Mouse, Rat,

    • 免疫原

      详见说明书

    • 亚型

      IGg

    • 形态

      粉末、液体、冻干粉

    • 应用范围

      Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200

    • 浓度

      1mg/ml

    • 保存条件

      -20 °C

    • 规格

      100ul

    FITC标记的血管内皮细胞生长因子受体3抗体
    英文名称 Anti-VEGFR3/FITC
    中文名称 FITC标记的血管内皮细胞生长因子受体3抗体
    别    名 Vascular endothelial growth factor receptor 3; VEGF Receptor 3; Tyrosine-protein kinase; Flt4; VEGFR3; AI323512; Chy; FLT4; FLT41; LMPH1A; LOC285682; PCL; VEGFR-3; fms-related tyrosine kinase 4; VGFR3_MOUSE.  
    规格价格 100ul/2980元 购买        大包装/询价
    说 明 书 100ul  
    研究领域 肿瘤  免疫学  信号转导  生长因子和激素  激酶和磷酸酶  细胞膜受体  血管内皮细胞  
    抗体来源 Rabbit
    克隆类型 Polyclonal
    交叉反应 Human, Mouse, Rat, 
    产品应用 Flow-Cyt=1:50-200 ICC=1:50-200 IF=1:50-200  
    not yet tested in other applications.
    optimal dilutions/concentrations should be determined by the end user.
    分 子 量 151kDa
    细胞定位 细胞膜 
    性    状 Lyophilized or Liquid
    浓    度 1mg/ml
    免 疫 原 KLH conjugated synthetic peptide derived from human VEGFR-3
    亚    型 IgG
    纯化方法 affinity purified by Protein A
    储 存 液 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
    保存条件 Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
    产品介绍 background:
    Vascular endothelial growth factors (VEGFs) are a family of closely related growth factors having a conserved pattern of eight cysteine esidues and sharing common VEGF receptors. VEGFs stimulate the proliferation of endothelial cells, induce angiogenesis, and increase vascular permeability in both large and small vessels. The mitogenic activity of VEGFs appears to be mediated by specific VEGF receptors. VEGF Receptor 3 is one of the five receptor tyrosine kinases (RTKs) (VEGF Receptor 1/Flt1, VEGF Receptor 2/KDR/Flk1, VEGF Receptor 3/Flt4, tie1 and tek/tie2) whose expression is almost exclusively restricted to endothelial cells

    Function:
    Tyrosine-protein kinase that acts as a cell-surface receptor for VEGFC and VEGFD, and plays an essential role in adult lymphangiogenesis and in the development of the vascular network and the cardiovascular system during embryonic development. Promotes proliferation, survival and migration of endothelial cells, and regulates angiogenic sprouting. Signaling by activated FLT4 leads to enhanced production of VEGFC, and to a lesser degree VEGFA, thereby creating a positive feedback loop that enhances FLT4 signaling. Modulates KDR signaling by forming heterodimers. Mediates activation of the MAPK1/ERK2, MAPK3/ERK1 signaling pathway, of MAPK8 and the JUN signaling pathway, and of the AKT1 signaling pathway. Phosphorylates SHC1. Mediates phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase. Promotes phosphorylation of MAPK8 at 'Thr-183' and 'Tyr-185', and of AKT1 at 'Ser-473'.

    Subunit:
    Interacts with VEGFC and VEGFD. Monomer in the absence of bound VEGFC or VEGFD. Homodimer in the presence of bound VEGFC or VEGFD. Can also form a heterodimer with KDR. Interacts with PTPN14; the interaction is enhanced by stimulation with VEGFC. Interacts with CRK, GRB2, PTK2/FAK1, SHC1, PIK3R1 and PTPN11/SHP-2. Identified in a complex with SRC and ITGB1.

    Subcellular Location:
    Cell membrane; Single-pass type I membrane protein. Cytoplasm. Nucleus. Note=Ligand-mediated autophosphorylation leads to rapid internalization. 
    Isoform 1: Cell membrane; Single-pass type I membrane protein. Note=Ligand-mediated autophosphorylation leads to rapid internalization. 
    Isoform 2: Cell membrane; Single-pass type I membrane protein. 
    Isoform 3: Secreted. Cytoplasm.

    Tissue Specificity:
    Detected in endothelial cells (at protein level). Widely expressed. Detected in fetal spleen, lung and brain. Detected in adult liver, muscle, thymus, placenta, lung, testis, ovary, prostate, heart, and kidney.

    Post-translational modifications:
    Autophosphorylated on tyrosine residues upon ligand binding. Autophosphorylation occurs in trans, i.e. one subunit of the dimeric receptor phosphorylates tyrosine residues on the other subunit. Phosphorylation in response to H(2)O(2) is mediated by a process that requires SRC and PRKCD activity. Phosphorylation at Tyr-1068 is required for autophosphorylation at additional tyrosine residues. Phosphorylation at Tyr-1063 and Tyr-1337 is important for interaction with CRK and subsequent activation of MAPK8. Phosphorylation at Tyr-1230, Tyr-1231 and Tyr-1337 is important for interaction with GRB2 and subsequent activation of the AKT1 and MAPK1/ERK2 and/or MAPK3/ERK1 signaling pathways. In response to endothelial cell adhesion onto collagen, can also be phosphorylated in the absence of FLT4 kinase activity by SRC.

    Similarity:
    Belongs to the protein kinase superfamily. Tyr protein kinase family. CSF-1/PDGF receptor subfamily. 
    Contains 7 Ig-like C2-type (immunoglobulin-like) domains. 
    Contains 1 protein kinase domain.

    Database links:

    Entrez Gene: 2324 Human

    Entrez Gene: 14257 Mouse

    Entrez Gene: 114110 Rat

    Omim: 136352 Human

    SwissProt: P35916 Human

    SwissProt: P35917 Mouse

    SwissProt: Q91ZT1 Rat

    Unigene: 646917 Human

    Unigene: 3291 Mouse

    Unigene: 81043 Rat



    Important Note:
    This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 

    VEGFR3又称FLt4主要在成熟组织的淋巴管内皮细胞上表达,VEGF-R3与淋巴管内皮细胞增殖和迁移有关,有刺激淋巴管新生的作用,目前多用于肿瘤转移方面的研究。

    风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。

    图标文献和实验
    相关实验
    • 生长因子在激活免疫细胞方面有哪些应用?

      子蛋白质或多肽,能够通过与细胞表面受体结合,调节细胞的增殖、分化和功能。它们在干细胞的自我更新、分化以及维持干细胞特性中发挥重要作用。 细胞因子在不同干细胞分化中的应用 a.胚胎干细胞(ESC)和诱导多能干细胞(iPSC) bFGF(碱性成纤维细胞生长因子):常用于维持胚胎干细胞和 iPSC 的未分化状态。 Activin A:用于诱导 iPSC 分化为内胚层细胞。 TGF-β超家族成员(如 BMP-4):可诱导 iPSC 分化为中胚层细胞。 VEGF(血管内皮生长因子):在诱导 iPSC 分化

    • 提高多色流式实验成功的 8 个 Tips

      Tip 1:补偿控制样品必须只染一种颜色 当细胞群同时向两个通道发射荧光时,可能是由于两个原因: 细胞群表达一种 Marker,该标记物被荧光染料偶联的抗体染色,在第二个通道中检测到荧光染料的荧光溢出。 细胞群表达两种 Markers,这些标记物被两种不同荧光染料染色,发射出的荧光到两个通道中。为了在补偿期间排除双阳性细胞的干扰,调节补偿应仅用单一染料染色。 Tip 2:样本中必须包含中位数比较的阴性和阳性细胞群 要正确调节补偿,必须比较溢出通道中阴性和阳性细胞的中位数荧

    • 血管内皮生长因子受体2(VEGFR2)酶联免疫分析(ELISA)

      依次加入 血管内皮生长因子受体2(VEGFR2) , 再与 HRP 标记血管内皮生长因子受体2(VEGFR2) 抗体结合,形成抗体 - 抗原 - 酶标抗体复合物,经过彻底洗涤后加底物 TMB 显色。 TMB 在 HRP 酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的 血管内皮生长因子受体2(VEGFR2) 呈正相关。用酶标仪在 450nm 波长下测定吸光度( OD 值),通过标准曲线计算样品中人血管内皮生长因子受体 2(VEGFR2) 浓度。  

    图标技术资料

    暂无技术资料 索取技术资料

    同类产品报价

    产品名称
    产品价格
    公司名称
    报价日期
    询价
    上海圻明生物科技有限公司
    2025年07月13日询价
    ¥2980
    上海联迈生物工程有限公司
    2025年07月14日询价
    ¥1770
    上海沪震实业有限公司
    2025年07月13日询价
    ¥600
    北京百奥莱博科技有限公司
    2025年07月14日询价
    ¥2400
    深圳市豪地华拓生物科技有限公司
    2025年07月10日询价
    FITC标记的血管内皮细胞生长因子受体3抗体
    ¥2980